Three independent and converging lines of established biological research — phylogenetic biomimetics, information-theoretic epigenetics, and bioelectric morphogenetic medicine — have each demonstrated in peer-reviewed experimental settings that cellular chronological state is not permanently fixed but is instead an informational configuration subject to external modulation and reversal. This paper proposes the Bioelectric Quantum Phase Resonance (BQPR) framework: a unified theoretical architecture that integrates these three biological control systems into a single non-invasive therapeutic apparatus — the Phase-Locked Resonance Cell (PLRC) — capable of executing targeted epigenetic entropy reset, oncogenic bioelectric normalization, and somatic cellular rejuvenation without the introduction of exogenous genetic material, viral vectors, or chemical agents. The biological evidence base is substantial and contemporary. The hydrozoan Turritopsis dohrnii demonstrates that complete ontogenetic reversal is biologically achievable via conserved molecular pathways (Matsumoto et al., 2019; Matsumoto and Miglietta, 2021). Harvard Medical School's Yang and Sinclair (2023) demonstrated that human cellular aging is a reversible epigenetic information-loss process, with youthful transcript profiles chemically restorable without genomic modification. Macip et al. (2024) extended median remaining lifespan in aged wild-type mice by 109 percent through OSK gene therapy. Levin (2014) and Levin and Martyniuk (2018) established the bioelectric code as a top-down morphogenetic control system capable of normalizing oncogenic cells by restoring healthy tissue voltage patterns. The National Cancer Institute hosted its inaugural Conference on Cancer Bioelectricity in September 2024 (Mathews et al., 2025). FDA-approved Tumor Treating Fields (TTFields) devices now demonstrate clinically validated electromagnetic cancer treatment across glioblastoma, mesothelioma, lung cancer, and pancreatic cancer (Khagi et al., 2025). The BQPR framework proposes that the five-stage Cascaded Josephson Matrix Filter (CJMF) — whose noise attenuation mathematics are derived in the companion MQPS paper (Bishop, 2026) — provides the precision phase-control architecture required to deliver bioelectric corrections at a fidelity exceeding any current clinical electromagnetic therapy. Three falsifiable experimental predictions are proposed. This paper does not claim to replace existing therapies; it proposes a theoretical integration architecture and identifies the experimental pathway toward validation.